Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio is a promising clinical stage biopharmaceutical company with an innovative drug pipeline targeting degenerative retinal diseases and metabolic diseases with unmet medical needs. Its lead candidate, tinlarebant, has shown promising results and has been granted multiple designations by the US FDA. With a potential NDA submission in 2Q26 and a potential commercial launch in 1Q27, combined with the company's plans for a sales team and broad label for patients above 12 years of age, we believe Belite Bio has great potential and we reiterate our Buy rating.

Bears say

Belite Bio is well-funded to complete the regulatory process, with a net loss of $77.6M and cash of $772.6M at the end of FY2025. However, with ongoing trials and limited product candidates, the company may struggle to generate significant revenue and reach profitability in the near future. The potential success of tinlarebant and LBS-009 will heavily impact the company's future performance and should be closely monitored.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $198, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $198, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.